Kevin C. Mannix | Teva Pharmaceutical Industries Ltd. |
Kåre Schultz | Teva Pharmaceutical Industries Ltd. |
Michael McClellan | Teva Pharmaceutical Industries Ltd. |
Brendan O'Grady | Teva Pharmaceutical Industries Ltd. |
Gregg Gilbert | Deutsche Bank Securities, Inc. |
Jason M. Gerberry | Bank of America Merrill Lynch |
Elliot Wilbur | Raymond James & Associates, Inc. |
Zhu Shen Ng | Morgan Stanley & Co. LLC |
Irina R. Koffler | Mizuho Securities USA LLC |
Liav Abraham | Citigroup Global Markets, Inc. |
Umer Raffat | Evercore Group LLC |
David A. Amsellem | Piper Jaffray & Co. |
Jami Rubin | Goldman Sachs & Co. LLC |
Ami Fadia | Leerink Partners LLC |
Rohit Vanjani | Guggenheim Securities LLC |
Aharon Gal | Sanford C. Bernstein & Co. LLC |
Ladies and gentlemen, thank you for standing by and welcome to the Teva First Quarter 2018 Financial Results. At this time, all participants are in a listen-only mode. There will be a presentation, followed by a question-and-answer session. I must also advise you the call is being recorded today, Thursday, May 3, 2018. I would now like to turn the conference over to your first speaker today, Kevin Mannix, Senior Vice President, Head of Investor Relations.